IP Library Granted Patent US 8,858,988
Granted Patent B2
US 8,858,988 · App. 13/505,978 · Granted Oct 14, 2014

Compositions comprising extracts of

Inventors: Guy Chamberland (Boucherville, CA); Peter Bollen (B-Drongen, BE)
Assignees: CuraPhyte Technologies Inc.; Nutriquine N.V.
A61L15/34A61L15/44A61K36/324A61K36/886A61L2300/62A61K36/53A61L2300/30A61K36/61A61L15/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,858,988
App. No.
13/505,978
Granted
Oct 14, 2014
Kind
B2
Abstract

Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil ( Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.

Claims (32)

1. A composition for treating sores, wounds, burns or other traumatized dermal tissues and skin injuries, formulated into a topical ointment, lotion or cream comprising about 2% by weight oil from the leaves of Melaleuca alternifolia (Tea Tree oil); about 2.8% by weight gum from the resin of Boswellia serrata (boswellia); about 1% by weight to about 10% by weight gel from the leaves of Aloe vera (Aloe); and about 0.4% by weight oil from the flower of Lavandula officinalis (Lavender).

2. The composition of claim 1 , further comprising Lanolin, Zinc oxide, Cod Liver oil, Paraffinum Liquidum, white petroleum jelly, Propyl hydroxybenzoate, Methyl hydroxybenzoate and water.

3. The composition of claim 2 , further comprising an alginate, a hydrocolloid, or combinations thereof.

4. The composition according to claim 1 , wherein the composition comprises about 50% to 79% by weight boswellic acids.

5. The composition according to claim 1 , wherein the Tea Tree oil contains at least 10% by weight terpinene-4-ol.

6. The composition according to claim 1 , further comprising one or more component or extract containing growth factors; an antibiotic; an analgesic; zinc oxide; vitamin A; vitamin E; an extract of Harpagophytum procumens (Devil's claw) root, Salix Alba (White Willow) plant or bark, Tanacetum Parthenium (Feverfew) herb or flower, Equisetum arvense (Horsetail), Spireae ulmaria (Dropwort), Betula alba (Birch), Urtica dioica (Stinging Nettle), Curcuma, longa (Tumeric), marine algae or Gotu kola ( Centella asiatica Linn.); total triterpenic fraction of Centella asiatica (TTECA);

or combinations thereof.

7. The composition according to claim 6 , wherein the component or extract containing growth factors comprises colostrum, whey, blood, tissue, or combinations thereof.

8. The composition according to claim 1 , further comprising a component to absorb wound exudates, slowly release the active agents, or both.

9. The composition according to claim 8 , wherein the one or more components to absorb wound exudates, slowly release the active agents or both is selected from the group consisting of alginate, chitosan, hydrocolloid, chitin, polyoligosaccharide, liposome, a slow-releasing polymer or agent, and combinations thereof.

10. The composition of claim 9 , wherein the hydrocolloid comprises a natural, chemically modified, or synthetic hydrocolloid, or a combination thereof.

11. The composition of claim 9 , wherein the alginate comprises calcium alginate.

12. The composition of claim 1 , further comprising one or more non-plant component selected from the group consisting of Lanolin, petroleum jelly, Paraffin oil, Zinc oxide, cod liver oil, vegetable oil, and paraffinium liquid.

13. The composition of claim 1 , further comprising a preservative.

14. The composition of claim 13 , wherein the preservative is a hydroxybenzoate.

15. The composition of claim 1 , further comprising a scent agent to camouflage the odour of the composition.

16. The composition of claim 15 , wherein the scent agent comprises an essential oil of a plant, flower, or combination thereof.

17. The composition of claim 1 , added to, coated on or embedded into a wound dressing or bandage.

18. The composition of claim 17 , wherein the wound dressing is a fibrous wound dressing or a dressing for applying directly to wounds for occlusion or semi-occlusion.

19. The composition of claim 1 , formulated within or on the surface of a medical device.

20. The composition of claim 19 , wherein the medical device is a dressing, a bandage, or other semi-occlusive or occlusive material used in wound care.

21. A medical device comprising the composition as defined in claim 1 , coated thereon or embedded within said medical device.

22. The medical device of claim 21 , wherein the composition is contained at least partially within particles or microparticles.

23. The medical device of claim 22 , wherein the particles or microparticles are liposomes.

24. The medical device of claim 22 , wherein the particles or microparticles comprising the composition are used to deliver or release active ingredients to the wound while maintaining semi-occlusion or complete occlusion.

25. The medical device of claim 21 , wherein the medical device is a dressing, a bandage, or other semi-occlusive or occlusive material used in wound care.

26. A method of treating sores, wounds, burns or other traumatized dermal tissues and skin injuries, comprising administering a composition as defined in claim 1 to a subject in need thereof.

27. The method of claim 26 , wherein the composition is applied daily until there is at least partial healing or amelioration of the sore, wound, burn or other traumatized dermal tissue or skin injury.

28. The method of claim 26 , wherein the method comprises treating acute wounds selected from the group consisting of heat burns, sun burns, traumatic injuries, surgical wounds, punctures, cracked heals, bites, insect bites and infected wounds.

29. The method of claim 26 , wherein the method comprises treating chronic wounds selected from the group consisting of venous leg ulcers, pressure sores or ulcers, ischemic ulcers and diabetic ulcers.

30. The method of claim 26 , wherein the subject is a mammal.

31. The method of claim 30 , wherein the mammal is a human.

Assignments (5)
SECURITY INTEREST Recorded Feb 11, 2016
From: JAMP PHARMA CORPORATION
To: BDC CAPITAL INC.
Reel/Frame 037764/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2015
From: CURAPHYTE TECHNOLOGIES INC.
To: JAMP PHARMA CORPORATION
Reel/Frame 036424/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2015
From: CURAPHYTE TECHNOLOGIES INC.
To: JAMP PHARMA CORPORATION
Reel/Frame 036362/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2014
From: BOLLEN, PETER
To: NUTRIQUINE N.V.
Reel/Frame 033722/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2014
From: CHAMBERLAND, GUY
To: CURAPHYTE TECHNOLOGIES INC.
Reel/Frame 033723/0118 →
Priority Claims (1)
CA 2684258 · Nov 3, 2009 · national
Continuity (1)
Related Publication 20120308637A1 · Dec 6, 2012